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CASE PRESENTATION
A 52-year-old white female with a history of profound
hypophosphatemia, muscle weakness, and multiple
debilitating atraumatic fractures was referred in March
2004 for evaluation at the Mineral Metabolism Clinic. Five
years prior, she had sustained bilateral rib fractures which
failed to heal. In May 2000, she was diagnosed with
primary hyperparathyroidism based on serum calcium of
10.4 mg/dl (reference range 8.4–10.2 mg/dl), parathyroid
hormone (PTH) of 97 pg/ml (reference 10–65 pg/ml),
phosphorus of 2.0 mg/dl (reference 2.5–4.5 mg/dl), and
alkaline phosphatase of 420 IU/l (reference 38–126 IU/l).
Bone density measured by dual energy X-ray
absorptiometry (DXA) revealed T-scores of 2.9 (lumbar
spine) and 3.5 (femoral neck), indicative of osteoporosis.
In July 2000, the patient underwent partial
parathyroidectomy with removal of two parathyroid
glands (histologic diagnosis: adenoma for left superior
gland, normal for left inferior gland). Intraoperatively,
serum PTH fell from 58 to 13 pg/ml at 24 min post-
excision. In the ensuing months, serum calcium
normalized, but PTH remained elevated and serum
phosphorus remained low. One year after the first
parathyroid surgery, the patient underwent a subtotal
parathyroidectomy (histologic diagnosis: hyperplasia),
leaving only about 20–30 mg of the right inferior gland,
and was placed on low dose calcitriol (0.5mg daily). Over
the next three years, she progressively lost mobility due to
muscle weakness, requiring assistance in ambulation.
She developed multiple additional atraumatic fractures
(bilateral superior and inferior pubic ramus, bilateral
femoral head, radial neck, ulnar, and multiple vertebral)
resulting in kyphosis. After repeated neurological and
rheumatological evaluations, she was referred to our
clinic. In June 2004, she complained of profound fatigue
and severe pain in the low back and thoracic area and
required a walker for ambulation. Physical examination
revealed a well-nourished kyphotic woman, with a
wide-based gait and generalized decreased muscle
strength (4/5). An iliac crest bone biopsy and clinical
biochemistry evaluation were performed.
BONE BIOPSY
The bone biopsy (Figure 1) revealed a marked increase in
osteoid parameters for both cortical and cancellous bone,
including osteoid volume (11.9 and 56.1% of total bone
volume, for cortical and cancellous bone respectively),
osteoid surface (78.9 and 93.6% of total bone surface), and
mean osteoid seam width (24 and 31 mm). Mineralized bone
volume and mean thickness were reduced in both cortical
and cancellous bone. Osteoblastic surfaces were present but
reduced for the amount of osteoid present. Resorptive
parameters were not increased and frankly low for cancellous
bone. Tetracycline labeling was absent in all sections
examined, indicating lack of new bone formation. Taken
together, these findings are consistent with osteomalacia
because of defective bone mineralization.
CLINICAL DIAGNOSIS
The results of the initial clinical biochemistry evaluation,
performed during a 4-day constant metabolic diet, are shown
in Table 1. In the absence of a family history of hypopho-
sphatemia, the combination of acquired severe hypopho-
sphatemia, renal phosphate wasting, osteomalacia, and
inappropriately low 1,25-dihydroxy vitamin D raised the
suspicion of tumor-induced osteomalacia (TIO). Consis-
tently, serum fibroblast growth factor 23 (FGF23) measured
by enzyme immunosorbent assay directed against the
t h e r e n a l c o n s u l t http://www.kidney-international.org
& 2009 International Society of Nephrology
Received 13 March 2008; revised 1 May 2008; accepted 6 May 2008;
published online 30 July 2008
Correspondence: Khashayar Sakhaee, Charles and Jane Pak Center for
Mineral Metabolism and Clinical Research, University of Texas Southwestern
Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390-8885, USA.
E-mail: khashayar.sakhaee@utsouthwestern.edu
Kidney International (2009) 76, 342–347; doi:10.1038/ki.2008.355;
published online 30 July 2008
342 Kidney International (2009) 76, 342–347
C-terminal molecule (Alpco, Salem, NH) was elevated:
573 RU/ml (reference o230 RU/ml). A search for an under-
lying tumor was initiated. Magnetic resonance imaging of the
chest and abdomen had been previously performed and were
unremarkable. An 111In-octreotide scintigraphy (octreotide
scan) was obtained in September 2004 and revealed an
inappropriate focus of uptake slightly to the left of the
midline of the head (Figure 2a). Single-photon emission
computed tomography revealed an intense focus of radio-
tracer in the midline, inferior to the cranial vault. Magnetic
resonance imaging of the orbit and face demonstrated a
1.5 1.4 1.4 cm rounded mass within the dorsal aspect of
the left nasal cavity (Figure 2b). The mass abutted the dorsal
aspect of the inferior nasal turbinate and nasal septum,
without invasion of the pterygoid musculature.
While awaiting surgery, in October 2004 the patient was
initiated on indomethacin 25 mg, p.o., t.i.d., both for bone
pain control and to evaluate the putative effect of
indomethacin on FGF23/phosphate metabolism (detailed in
Discussion). No significant improvement of hypophosphate-
mia was noted and indomethacin was discontinued after 4
weeks. The patient was placed on replacement therapy with
calcitriol (0.25 mg, p.o., t.i.d.) and phosphate (750 mg, p.o.,
t.i.d.) until a week before surgery.
A transnasal, endoscopic excision of the nasal mass (Figure
2c) was performed in December 2004. Pathological examina-
tion showed diffuse hypercellular spindle cell proliferation
arranged in an ill-defined fascicular growth pattern (Figure
3a). The neoplastic cells were mostly short spindled with
round to oval nuclei showing mild to moderate cytological
atypia (mild hyperchromasia and mild to moderate nuclear
pleomorphism). The mitotic rate was low (1–2 per 10 high-
power fields). The stroma exhibited prominent capillary-like,
thick-walled, and hemangiopericytic-like vessels. Multiple
osteoclast-like giant cells (Figure 3b) and focal extracellular
mineralized chondroid matrix (Figure 3c) were noted. No
necrosis was identified. The pathological diagnosis was
phosphaturic mesenchymal tumor, mixed connective tissue
variant. Immunohistochemical analysis of paraffin-fixed
sections using a monoclonal anti-human FGF23 antibody
showed expression of FGF23 protein in the cytoplasm of
isolated cells in the excised tumor (Figure 3d–f).
CLINICAL FOLLOW-UP
Figure 4 shows the evolution of markers of phosphate
metabolism over 33 months starting from our initial
evaluation, including 27 months post-surgery. Postoperative
clinical improvement and normalization of biochemical
abnormalities confirmed the initial diagnosis of TIO. Serum
phosphorus normalized within 1 week after tumor removal.
A rapid decrease in serum calcium (to 7.5 mg/100 ml within 24 h)
prompted concern of hungry bone syndrome, and further
hypocalcemia was prevented with temporary calcium sup-
plementation. Serum 1,25-dihydroxy vitamin D levels
normalized 24 h post-intervention, became elevated after 1
week (101 pg/ml), likely because of an abrupt increase in
bone mineralization (Figure 4d), and returned to normal 3
months postoperatively. At that time, intestinal calcium
absorption measured by dual isotope was increased
(77%). Repeat octreotide scan 5 months post-intervention
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Figure 1 | Histological sections of bone from our patient with
tumor-induced osteomalacia (b, d) and from an age- and
gender-matched patient with normal bone structure (a, c),
used for comparison. (a) Normal bone with a very thin layer of
osteoid. (b) Undercalcified iliac trabecular bone (stained with
toluidine blue) is covered by excessive amounts of osteoid
(stained light blue, arrow; original magnification  100). Both
cortical and cancellous structural indices of thickness and volume
were reduced compared to normal. (c) Fluorescence microscopy
of bone after double tetracycline labeling shows double
fluorescent labels in a patient with normal bone mineralization.
(d) Tetracycline uptake was severely reduced in the patient as
shown by representative trabeculae with no visible label (original
magnification  160). The patient’s findings are consistent with a
bone mineralization defect (osteomalacia).
Table 1 | Initial metabolic evaluation
Serum calcium 8.5 mg/100 ml (reference
8.4–10.2 mg/100 ml)
Serum phosphorus 0.7 mg/100 ml (reference
2.5–4.5 mg/100 ml)
Parathyroid hormone 89 pg/ml (reference
10–65 pg/ml)
Serum alkaline phosphatase 168 IU/l (reference
38–126 IU/l)
Serum creatinine 0.7 mg/100 ml (reference
0.8–1.4 mg/100 ml)
Serum 25-hydroxy vitamin D 30 ng/ml (reference 5–60 ng/ml)
Serum 1,25-dihydroxy vitamin D 6 pg/ml (reference
10–65 pg/ml)
Renal fractional excretion of
phosphate
40%
Renal threshold phosphate
concentration (TmP/GFR)
0.25–0.30
mg/100 ml
(reference
2.5–4.35 mg/100 ml)
Intestinal calcium absorption
(dual-isotope method)
23% (mean normal 50%)
Laboratory data were collected during a 4-day constant metabolic diet containing
400 mg calcium, 100 mEq sodium, and 800 mg phosphate daily.
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demonstrated no abnormal tracer uptake (Figure 2d). Bone
density at the lumbar spine measured by dual-energy X-ray
absorptiometry 6 months after surgery showed a 21%
improvement. During 27 months of postoperative follow-
up, the patient’s clinical complaints of bone pain and muscle
weakness progressively resolved, and self-ambulation was
restored.
DISCUSSION
TIO is a rare paraneoplastic syndrome characterized by renal
phosphate wasting, hypophosphatemia, inappropriately nor-
mal or low serum 1,25-dihydroxy vitamin D, and inadequate
bone mineralization.1,2 The clinical manifestations of TIO
include fatigue, muscle weakness, bone pain (that can mimic
joint pain), and insufficiency fractures (‘spontaneous’
fractures, caused by physiological levels of mechanical stress
exerted upon weakened bone), in the absence of a family
history of renal phosphate wasting and/or bone disorders.
Disease progress can be slow and insidious, mimicking other
rheumatological, neurological, or endocrine disorders, and
thus correct diagnosis can be delayed for years or missed
altogether. Without intervention, patients become progres-
sively debilitated, experience a markedly decreased quality of
life, and are at risk of life-threatening complications.
Identification and surgical removal of the offending tumor
followed by normalization of phosphate metabolism provides
both definitive diagnosis and cure of TIO.
Phosphorus homeostasis
Phosphorus homeostasis is maintained by the interplay
between net intestinal absorption, tissue and bone turnover,
and renal excretion, with net intestinal absorption matching
renal excretion under balance conditions. The kidney
assumes a pivotal role in maintaining total body phosphorus
balance. Phosphorus circulating as unbound phosphate is
freely filtered at the glomerulus and reabsorbed primarily
across the proximal tubule. Renal reabsorption of phosphate
is regulated by multiple humoral factors, including a class of
incompletely understood circulating phosphaturic factors
collectively called phosphatonins.3–6 These were initially
discovered as humoral factors secreted by the tumors of
patients with TIO, and include FGF23, FGF7, matrix
extracellular phosphoglycoprotein, and secreted frizzled-
related protein 4. Phosphatonins downregulate renal phos-
phate reabsorption at least in part by decreasing the
abundance of apical sodium/phosphate co-transporters
(NaPi-IIa) in the proximal tubule.6 FGF23 is the most
studied phosphatonin, and has a causative role in the
pathogenesis of hereditary hypophosphatemias—X-linked
hypophosphatemic rickets (XLHR) and autosomal dominant
hypophosphatemic rickets—as well as in some cases of
acquired hypophosphatemia from TIO.7,8
Etiology of hypophosphatemia
Hypophosphatemia can be caused by inadequate dietary
intake, decreased intestinal absorption, excessive urinary
excretion, or the shift of phosphate from serum into cells
and/or bone. Inappropriately high excretion (renal wasting)
of phosphate occurs in various genetic and acquired
disorders. One common cause is hyperparathyroidism, which
is usually associated with moderate hypophosphatemia.
Parathyroid hormone (PTH)-independent renal phosphate
wasting is usually more severe and may occur because of
intrinsic proximal tubular defects (Fanconi syndrome), or
because of increased production and/or decreased degrada-
tion of phosphatonins. Phosphatonin-related disorders may
in turn be genetic (XLHR, autosomal dominant hypo-
phosphatemic rickets, fibrous dysplasia), or acquired (TIO).
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Figure 2 | Radiographic and macroscopic findings. (a) 111In-octreotide scintigraphy 3 months before surgery, demonstrating a focus
of enhanced inappropriate uptake slightly to the left of the midline of the head (arrow). (b) Magnetic resonance imaging of the head
shows a 1.5 1.4 1.4 cm rounded mass (arrow) within the dorsal aspect of the left nasal cavity. (c) Macroscopic image of the very
vascular tumor in situ, just before surgical removal. (d) 111In-octreotide scintigraphy 5 months post-surgery, demonstrating lack of
tracer uptake in the former location of the tumor.
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Of note, secondary hyperparathyroidism and tertiary hyper-
parathyroidism have been observed in patients with XLHR
and TIO9,10 and may further contribute to phosphate loss in
these patients. The mechanism for this is uncertain, but may
be related to reduced 1,25-dihydroxy vitamin D levels leading
to decreased intestinal absorption of calcium, hypocalcemia,
and consequent upregulation of PTH secretion. Hyperpar-
athyroidism in our patient was initially diagnosed as primary,
but in retrospect it is reasonable to suggest that it was actually
secondary or tertiary.
Evaluation of hypophosphatemia
Understanding the mechanism of hypophosphatemia is
critical for correct diagnosis. Renal phosphate wasting, a
hallmark of TIO, should be investigated in any patient with
persistent hypophosphatemia. Determination of phosphate
clearance and fractional excretion of phosphate do not
distinguish true renal phosphate wasting (inappropriate
reabsorption from the glomerular filtrate) from other causes
of abnormally elevated phosphate excretion (increased net
renal inflow of phosphate and/or increased glomerular
filtration rate (GFR), exceeding a normal reabsorptive
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Figure 3 | Histological and immunohistochemical analysis of
paraffin-fixed tumor sections. (a–c) Hematoxylin and eosin
staining showing (a) sinonasal mucosa with underlying solid
proliferation of short spindle and oval cells with bland
euchromatic nuclei and with no mitoses easily noted,
(b) osteoclast-like giant cells (arrowhead), and (c) focal mineralized
extracellular matrix. (d, e: original magnification  100 and
 400) Staining with a monoclonal anti-human FGF23 antibody
(R&D Systems, Minneapolis, MN) and a labeled streptavidin-biotin
chromogen detection system (IHC kit, Biochain, Hayward, CA).
Sections were counterstained with Mayer’s Hematoxylin (Volu-Sol,
Salt Lake City, UT). FGF23 was expressed in the cytosol of isolated
cells (in brown, arrowheads). No staining was observed when the
anti-human FGF23 antibody was omitted (f, negative control).
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Figure 4 | Biochemical markers of phosphate metabolism
pre- and post-surgery. The time of surgery is represented by
the dashed line. (a) Renal threshold phosphate concentration
TmP/GFR. (b) Serum FGF23. (c) Serum alkaline phosphatase.
(d) Serum 1,25-dihydroxy vitamin D. (e) Serum parathyroid hormone.
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capacity). Renal wasting can be confirmed by using the
nomogram of Walton and Bijvoet11 to derive renal threshold
phosphate concentration (TmP/GFR) from serum phos-
phorus and tubular reabsorption of phosphate
(TRP¼ 1–phosphate clearance/creatinine clearance, using
fasting urine and serum phosphate and creatinine). A low
TmP/GFR in spite of hypophosphatemia is indicative of renal
phosphate wasting.
The role of FGF23
If FGF23 is markedly increased in the absence of a family
history of hypophosphatemia, TIO is likely—although
approximately 20% of XLHR cases are because of sporadic
mutations and thus have a similar presentation.12 However, a
normal FGF23 level does not exclude TIO, as other tumor-
secreted phosphatonins may be involved and are not
measured. FGF23 was likely the offending phosphatonin in
our case, as FGF23 protein was expressed in the excised
tumor (Figure 3d–f), and serum FGF23 normalized after
surgery (Figure 4b).
Tumor localization
A search for an underlying tumor should be initiated as soon
as the clinical and biochemical findings indicate that TIO is
likely. Various tumor locations have been described, includ-
ing distal extremities, and, most commonly, the nasopharynx
and sinuses. Plain radiographs, computed tomography,
magnetic resonance imaging, and even positron-emission
tomography scanning have been successfully used to localize
TIO tumors, and computed-tomography-guided fine-needle
biopsy of the tumor has been used to aid in diagnosis. When
other imaging techniques fail to identify the tumor (as was
the case in our patient), octreotide scan should be
considered.13,14 This technique has high specificity but a
negative octreotide scan does not exclude TIO, as some but
not all TIO tumors have surface somatostatin receptors.
Selective venous sampling for FGF23 has also been success-
fully used to localize FGF23-secreting tumors.15,16
Histopathology
Most tumors associated with TIO are slow-growing, benign,
polymorphous neoplasms of mesenchymal origin, classified
as osteoblastoma-like, ossifying fibrous-like, non-ossifying
fibrous-like, and phosphaturic mesenchymal tumor, mixed
connective tissue variant.17 Of these, phosphaturic mesench-
ymal tumor, mixed connective tissue variant is the most
common, and contains characteristic spindle-shaped neo-
plastic cells with low or absent mitotic activity in a matrix
with calcifications, osteoclast-like giant cells, and rich
microvasculature.18 Rarely, TIO can result from neuro-
fibromatosis, fibrous dysplasia of bone, carcinomas, or
metastases.17,18
Treatment
Complete removal of the underlying tumor (and thus
removal of the source of excess circulating phosphatonins)
is to date the only definitive treatment. In most cases this
involves surgical resection, but successful computed-tomo-
graphy-guided radiofrequency ablation of a TIO tumor has
also been reported.19 Before surgery or in nonexcisable
tumors (failed localization or surgical contraindication),
aggressive phosphate and calcitriol replacement can improve
the symptoms, normalize serum phosphorus, but does not
improve renal phosphate wasting. Treatment with unlabeled
octreotide was attempted with mixed results in patients with
somatostatin receptor-positive tumors (as established by
radiolabeled octreotide scan).20,21
Effect of indomethacin
The therapeutic trial with indomethacin in our patient was
prompted by previous findings in hyp mice. The hyp mouse
is a murine model of XLHR with decreased FGF23
degradation and increased urinary prostaglandin E2 excre-
tion. Treatment with indomethacin led to amelioration of
hypophosphatemia and fractional excretion of phosphate in
these mice, without changes in GFR.22 To our knowledge, this
intervention has not been attempted in humans with renal
phosphate wasting. The lack of improvement in our patient
may be because of insufficient dosage (a higher dose is
however not recommended), or because of inherent differ-
ences between human TIO and the hyp mouse model.
SUMMARY
In our patient, TIO remained undiagnosed for several years.
Careful metabolic evaluation and extensive investigations
eventually led to the diagnosis, and TIO was cured by surgical
removal of the offending tumor. We emphasize the
importance of determining serum phosphorus and TmP/
GFR and considering TIO early in the differential diagnosis
of unexplained persistent bone pain, apparent joint pain,
muscle weakness, and spontaneous fractures.
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